Compare Moderna, Inc. (MRNA) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sirius XM Holdings Inc — how do they compare? Moderna, Inc. trades at $221.35 (market cap $78.65B), while Sirius XM Holdings Inc trades at $26.64 (market cap $8.87B). The key difference: Moderna, Inc. is far larger — about 8.9× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Sirius XM Holdings Inc for 102 Days on average.
| MRNA | SIRI | |
|---|---|---|
Market Cap | $78.65B | $8.87B |
Volume | 37,373,437 | 4,324,672 |
Sector | Health | Media |
52-Week High | $203.46 | $32.59 |
52-Week Low | $22.36 | $19.92 |
Typical Hold Time | 59 Days | 102 Days |
Enterprise Value | $74.80B | $18.16B |
Dividend Yield | — | 4.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Sirius XM (SIRI) trades at $26.67, up 2.77% today, with mixed technical signals showing neutral momentum. The stock shows attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, while recent earnings have been inconsistent with two misses and one beat in the last three quarters. The company maintains solid profitability with 47.36% gross margins and positive cash flow generation, supported by recent strategic initiatives including YouTube partnerships and advertising expansion.
The investment case balances value appeal against execution risks. Analyst consensus remains bullish with a $34.43 price target (29% upside), though investors face risks from competitive pressures and inconsistent earnings performance. The company's strong cash flow and strategic partnerships provide growth catalysts, but requires monitoring of subscription trends and advertising revenue execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
